142 related articles for article (PubMed ID: 11728835)
41. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.
Hogarty GE; McEvoy JP; Munetz M; DiBarry AL; Bartone P; Cather R; Cooley SJ; Ulrich RF; Carter M; Madonia MJ
Arch Gen Psychiatry; 1988 Sep; 45(9):797-805. PubMed ID: 3415422
[TBL] [Abstract][Full Text] [Related]
42. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
Altamura AC; Curry SH; Montgomery S; Wiles DH
Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
[TBL] [Abstract][Full Text] [Related]
43. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
44. Fluphenazine plasma levels and clinical response.
Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
[TBL] [Abstract][Full Text] [Related]
45. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
[TBL] [Abstract][Full Text] [Related]
46. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
[TBL] [Abstract][Full Text] [Related]
47. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
[TBL] [Abstract][Full Text] [Related]
48. A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
Haslam MT; Bromham BM; Schiff AA
Acta Psychiatr Scand; 1975 Feb; 51(2):92-100. PubMed ID: 1091124
[TBL] [Abstract][Full Text] [Related]
49. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia.
Pinto R; Bannerjee A; Ghosh N
Acta Psychiatr Scand; 1979 Oct; 60(4):313-22. PubMed ID: 390972
[TBL] [Abstract][Full Text] [Related]
50. Fluphenazine enanthate in the outpatient treatment of late paraphrenia.
Raskind M; Alvarez C; Herlin S
J Am Geriatr Soc; 1979 Oct; 27(10):459-63. PubMed ID: 469146
[TBL] [Abstract][Full Text] [Related]
51. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
Leong OK; Wong KE; Tay WK; Gill RC
Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
[TBL] [Abstract][Full Text] [Related]
52. Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine.
Aravagiri M; Marder SR; Van Putten T; Hawes EM; McKay G; Midha KK
Ther Drug Monit; 1994 Feb; 16(1):21-9. PubMed ID: 8160250
[TBL] [Abstract][Full Text] [Related]
53. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
[TBL] [Abstract][Full Text] [Related]
54. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
55. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
Soni SD; Sampath G; Shah A; Krska J
Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
[TBL] [Abstract][Full Text] [Related]
56. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
Zhang YF
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug; 14(3):182-5. PubMed ID: 7333179
[No Abstract] [Full Text] [Related]
57. Persistence of fluphenazine in plasma after decanoate withdrawal.
Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
[TBL] [Abstract][Full Text] [Related]
58. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
Russell N; Landmark J; Merskey H; Turpin T
Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
[TBL] [Abstract][Full Text] [Related]
59. Depot fluphenazine decanoate and enanthate for schizophrenia.
David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
[TBL] [Abstract][Full Text] [Related]
60. Plasma levels of fluphenazine and prolactin in psychiatric patients.
Kitamura T; McGovern DA; Imlah NW; Wiles D; Schiff AA
Eur Arch Psychiatry Neurol Sci; 1988 Sep; 237(6):320-6. PubMed ID: 3181218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
